Gut bacteria boosts lung cancer treatment in new trial
NCT ID NCT07534033
First seen May 06, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This study tests whether a daily probiotic called LR607 can make standard chemo-immunotherapy more effective for people with stage IIB-IIIB non-small cell lung cancer that can be surgically removed. About 46 adults will take the probiotic for 3 months alongside their treatment. The main goal is to see if this combination reduces the amount of tumor left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC DIAGNOSED BY HISTOLOGY OR CYTOLOGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhu Jiang Hospital of Southern Medical University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.